^
Association details:
| Biomarker: | BRCA mutation |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | AiTan (rivoceranib) (VEGFR-2 inhibitor) + AiRuiYi (fluzoparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Hengrui’s HER2- Breast Cancer Combo Awarded Breakthrough Status
Published date:
04/03/2024
Excerpt:
...China-based Jiangsu Hengrui Medicine Co., Ltd was granted breakthrough therapy designation (BTD) for the treatment of HER2 negative breast cancer with gBRCA mutation in China.
